Dawn of CAR-T cell therapy in autoimmune diseases

作     者：Yuxin Liu Minghao Dong Yunhui Chu Luoqi Zhou Yunfan You Xiaowei Pang Sheng Yang Luyang Zhang Lian Chen Lifang Zhu Jun Xiao Wei Wang Chuan Qin Daishi Tian Yuxin Liu;Minghao Dong;Yunhui Chu;Luoqi Zhou;Yunfan You;Xiaowei Pang;Sheng Yang;Luyang Zhang;Lian Chen;Lifang Zhu;Jun Xiao;Wei Wang;Chuan Qin;Daishi Tian

作者机构：Department of NeurologyTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030China Hubei Key Laboratory of Neural Injury and Functional ReconstructionHuazhong University of Science and TechnologyWuhanHubei 430030China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2024年第137卷第10期

页      面：1140-1150页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Ministry of Science and Technology China Brain Initiative Grant STI2030-Major Projects(No.2022ZD0204700) National Natural Science Foundation of China(Nos.82371404,82271341,82071380,and 81873743) Knowledge Innovation Program of Wuhan Shuguang Project(No.2022020801020454) 

主　　题：CAR-T cell therapy Autoimmune disease Immunotherapy Multiple sclerosis Neuromyelitis optica spectrum disorder Systemic lupus erythematosus 

摘      要：Chimeric antigen receptor(CAR)-T cell therapy has achieved remarkable success in the treatment of hematological *** on the immunomodulatory capability of CAR-T cells,efforts have turned toward exploring their potential in treating autoimmune *** analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases,covering a range of subtypes such as systemic lupus erythematosus,multiple sclerosis,among ***-T therapy holds promise in mitigating several shortcomings,including the indiscriminate suppression of the immune system by traditional immunosuppressants,and non-sustaining therapeutic levels of monoclonal antibodies due to inherent pharmacokinetic *** persisting and proliferating in vivo,CAR-T cells can offer a tailored and precise *** paper reviewed preclinical experiments and clinical trials involving CAR-T and CAR-related therapies in various autoimmune diseases,incorporating innovations well-studied in the field of hematological tumors,aiming to explore a safe and effective therapeutic option for relapsed/refractory autoimmune diseases.